Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...

Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.

New first-line option for patients with pMMR and dMMR tumours in England NICE has recommended KEYTRUDA (pembrolizumab) with ...

An artificial intelligence-based image analysis model has more accurately predicted cancer biomarkers and outcomes compared with conventional methods.

The UK’s National Institute for Health and Care Excellence (NICE) on August 6 recommended the use of US pharma giant Merck & ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...